Single-center, Open-label, Non-randomized, Two-period Sequential Treatment Study to Assess the Effect of Neomycin on the Pharmacokinetics of Regorafenib in Healthy Male Subjects

Trial Profile

Single-center, Open-label, Non-randomized, Two-period Sequential Treatment Study to Assess the Effect of Neomycin on the Pharmacokinetics of Regorafenib in Healthy Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Jul 2014

At a glance

  • Drugs Regorafenib (Primary) ; Neomycin
  • Indications Cancer
  • Focus Pharmacokinetics
  • Sponsors Bayer
  • Most Recent Events

    • 19 May 2014 Trial status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Mar 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 06 Jan 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top